Cited by 175Antibiotic Use and ResistanceAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and Efficacy

Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries

Open access
Pauwels, Ines, Versporten, Ann, Drapier, Nico, Vlieghe, Erika, Goossens, Herman, the Global-PPS network, Koraqi, Andi, Hoxha, Iris +190 more·2021·Journal of Antimicrobial Chemotherapy

Abstract

OBJECTIVES: The WHO Access, Watch and Reserve (AWaRe) classification has been developed to support countries and hospitals in promoting rational use of antibiotics while improving access to these essential medicines. We aimed to describe patterns of worldwide antibiotic use according to the AWaRe classification in the adult inpatient population. METHODS: The Global Point Prevalence Survey on Antimicrobial Consumption and Resistance (Global-PPS) collects hospital antibiotic use data using a standardized PPS methodology. Global-PPS 2015, 2017 and 2018 data, collected by 664 hospitals in 69 countries, were categorized into AWaRe groups to calculate proportional AWaRe use, Access-to-Watch ratios and the most common indications for treatment with selected Watch antibiotics. Only prescriptions for systemic antibiotics on adult inpatient wards were analysed. RESULTS: Regional Access use ranged from 28.4% in West and Central Asia to 57.7% in Oceania, whereas Watch use was lowest in Oceania (41.3%) and highest in West and Central Asia (66.1%). Reserve use ranged from 0.03% in sub-Saharan Africa to 4.7% in Latin America. There were large differences in AWaRe prescribing at country level. Watch antibiotics were prescribed for a range of very different indications worldwide, both for therapeutic and prophylactic use. CONCLUSIONS: We observed considerable variations in AWaRe prescribing and high use of Watch antibiotics, particularly in lower- and upper-middle-income countries, followed by high-income countries. The WHO AWaRe classification has an instrumental role to play in local and national stewardship activities to assess prescribing patterns and to inform and evaluate stewardship activities.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/dkab050

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Data were collected using a structured checklist that was pre-tested and developed based on the WHO data abstraction form and WHO AWaRe 2023 classification.

    “Data were collected from the prescriptions of the outpatients, using a structured checklist that was pre-tested and developed based on the WHO data abstraction form for selected drug use indicators, and WHO AWaRe 2023 antibiotics classification framework7,8.”

    From Antibiotic-prescribing patterns in outpatient departments from a tertiary care hospital in Manipur using WHO AWaRe classification (2025) · cites this paper as [7]

    The Methods (Data analysis; page not provided) confirm that the paper uses the WHO AWaRe framework, but specify the 2019 classification, not the 2023 version. The Methods (Data collection; page not provided) describe a standardized survey of hospitalized patients, not outpatient prescriptions collected with a pre-tested checklist based on a WHO data abstraction form. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • WHO recommends at least 600 encounters for investigating drug use in healthcare facilities.

    “WHO recommends at least 600 encounters (prescriptions), with greater number, if possible, for investigating drug use in healthcare facilities7.”

    From Antibiotic-prescribing patterns in outpatient departments from a tertiary care hospital in Manipur using WHO AWaRe classification (2025) · cites this paper as [7]

    The Methods (Data collection) describes a point-prevalence survey of hospital antimicrobial prescribing, and the Discussion (Limitations) discusses participation and representativeness. Neither states that WHO recommends at least 600 encounters for investigating drug use in healthcare facilities; searches for the 600-encounter threshold and a minimum sample size found no supporting passage in our copy. (LLM, conf=0.72)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pauwels, I., Versporten, A., Drapier, N., Vlieghe, E., Goossens, H., the Global-PPS network, Koraqi, A., Hoxha, I., Tafaj, S., Cornistein, W., Quiros, R., Hojman, M., Ghazaryan, L., Horne, K., Cairns, K., Doukas, F., Gottlieb, T., Sermijn, E., Verhamme, K., Brands, C., Van Herendael, B., Filippin, L., Vandewal, W., Konopnicki, D., Maillart, E., Teixeira Lopes, L., Papin, P., Smits, I., Jansens, H., Bartholomeus, S., Van den Abeele, A.-M., Steyaert, S., Piette, A., Buyle, F., Cartuyvels, R., Jonckheere, S., Wybo, I., Vanneste, L., Mathieu, D., Firre, E., Westelinck, V., Gadisseux, P., Dugernier, T., Bafort, K., Gonissen, V., Vanderper, V., Gabriels, P., Weekers, F., Michel, P., Van Liedekerke, A., Costers, M., Catry, B., Dedeic-Ljubovic, A., Gales, A. C., Matos Porto, A. P., Figueiredo Costa, S., Keuleyan, E., Beidi, A., Cissohko, Y., Blakwe, H., Batchaya Basile, N., German, G. J., Lutes, S., Boswell, J., Mertz, D., Nguyen, T., MacLaggan, T., Landry, D., Ang, A., Thirion, D. J. G., Frenette, C., Émond, Y., Roberts, J., Chang, S., Kosar, J., Valiquette, L., Dutrisac, G., Afra, K., McGeer, A., Carrier, M., Grant, J., Labarca, J., Carvajal, C., Lin, H., Wang, Q., Yang, J., Yang, W., Cortes, J. A., Villalobos-Vindas, J., Ramírez-Valverde, C., Horvatic, J., Pristas, I., Paphitou, N., Rummukainen, M.-L., Froissart, A., Vanhems, P., Pagava, K., Korinteli, I., Brandt, T., Gaertner, J., Enimil, A., Roilides, E., Hajdú, E., Sengupta, S., Singh, S., Patil, P., Poojary, A., Soltani, J., Pouladfar, G., Jafarpour, Z., Alinia, C., Ameen, H., Fitzgerald, D., Paul, M., Maor, Y., Strahilevitz, J., Chowers, M., Temkin, E., Luca, A., Ishibashi, N., Gu, Y., Darwish Elhajji, F., Karabukayeva, A., Raka, D., Kambaralieva, B., Zarakauska, L., Zarb, P., Hernandez Chena, B. E., Gonzalez-Diaz, E., Corona-Meléndez, J., Torres Erazo, D. S., Loza-Jalil, S. E., Molina, J., Candelas, J. A., Mijovic, G., Duborija-Kovacevic, N., Jong, E., Kluytmans, J., van Elzakker, E., Schweitzer, V., Davies, N., Iregbu, K., Nwajiobi-Princewill, P., Nwafia, I., Fasuyi, T., Aboderin, A., Elikwu, C. J., Fadeyi, A., Ola-Bello, O., Oduyebo, O., Adedosu, A. N., Ekuma, A., Shaqiri, E., Saleem, Z., De Los Reyes, M. R., Tavares, L., Kim, N. J., Rachina, S., Alharthi, A. R., Enani, M., Faried, O., Mirghani, M., Carevic, B., Radulovic, L., Dragovac, G., Tan, S. H., Taljaard, J., Chibabhai, V., Joiner, J., Caston, J. J., Núñez-Núñez, M., Martínez-Marcos, F. J., Ojeda-Burgos, G., Menendez, M. D., Retamar, P., Corzo, J. E., Rattanaumpawan, P., Salou, M., Mnif, B., Oncul, A., Babigumira, P. A., Olweny, J., Marshall, E., McCorry, A., Aldeyab, M., Khanna, P., Gormley, C., Maloney, S., Cooper, M., Blackburn, L., Gessner-Wharton, M., Vu, L., Greer, N., Gawrys, G., Kronmann, L., Rios, E., Hudson, M., & Lindholm, D. A.
Affiliations
University of Antwerp (BE)
Corresponding author
Pauwels, Ines
Venue
Journal of Antimicrobial Chemotherapy
Published
2021-04-05
Volume
76
Issue
6
Pages
1614-1624
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W3143871140
Cited by
175
References
30
Citations by year
2026: 25 · 2025: 43 · 2024: 42 · 2023: 28 · 2022: 27 · 2021: 10
FWCI
15.73
Type
journal article
Language
en
Open access
Locations
  • Journal of Antimicrobial Chemotherapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc)
  • Huddersfield Research Portal (University of Huddersfield) (submittedVersion, cc-by-nc)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • The Global Point Prevalence Survey is coordinated by the University of Antwerp
  • Methusalem grant to Herman Goossens from the Flemish government
Topics
  • Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antibiotic Use and Resistance
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
  • Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
Keywords
antibiotic prescribing patterns, hospital antibiotic use, rational antibiotic use, antimicrobial stewardship, point prevalence survey, Watch antibiotics, hospitalized adults, antimicrobial resistance
MeSH terms
Adult, Anti-Infective Agents, Anti-Bacterial Agents, Hospitals, Humans, World Health Organization, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review